Nephrectomy is necessary in the treatment of metastatic renal cell carcinoma
- PMID: 20165582
- PMCID: PMC2812002
- DOI: 10.5489/cuaj.778
Nephrectomy is necessary in the treatment of metastatic renal cell carcinoma
Similar articles
-
Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.Int J Urol. 2021 Apr;28(4):369-375. doi: 10.1111/iju.14466. Epub 2020 Dec 12. Int J Urol. 2021. PMID: 33314387
-
Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation.J Urol. 1997 Sep;158(3 Pt 1):733-9. doi: 10.1097/00005392-199709000-00011. J Urol. 1997. PMID: 9258070
-
New prognostic model for synchronous metastatic renal cell carcinoma.Int J Urol. 2020 May;27(5):448-456. doi: 10.1111/iju.14215. Epub 2020 Mar 23. Int J Urol. 2020. PMID: 32207204
-
Cytoreductive nephrectomy in metastatic renal cell carcinoma.Curr Opin Urol. 2008 Sep;18(5):474-80. doi: 10.1097/MOU.0b013e32830a4f21. Curr Opin Urol. 2008. PMID: 18670270 Review.
-
Pancreatic metastasis from renal carcinoma managed by Whipple resection. A case report and literature review of metastatic pattern, surgical management and outcome.JOP. 2009 Jul 6;10(4):413-8. JOP. 2009. PMID: 19581746 Review.
Cited by
-
An evolutionary explanation for the perturbation of the dynamics of metastatic tumors induced by surgery and acute inflammation.Cancers (Basel). 2011 Mar 2;3(1):945-70. doi: 10.3390/cancers3010945. Cancers (Basel). 2011. PMID: 24212648 Free PMC article.
-
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.Eur Urol Open Sci. 2024 Mar 25;63:71-80. doi: 10.1016/j.euros.2024.02.001. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38572300 Free PMC article.
References
-
- Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9. - PubMed
-
- Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet. 2001;358:966–70. - PubMed
-
- Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071–6. - PubMed
-
- Belldegrun A, Shvarts O, Figlin RA. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl1):S88–92. - PubMed
-
- Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 2009;73:342–6. - PubMed
LinkOut - more resources
Full Text Sources